fbpx
Home > Events > CPHI South East Asia: Pharmacogenomics – Drugs That Kill

CPHI South East Asia 2025
Panel Recap: Pharmacogenomics - Drugs That Kill?

Convention on Pharmacuetical Ingredients (CPHI)

Picture taken during panel discussion in CPHI SEA 2025 involving Dr Rebecca, representing Precision Diagnostics
Picture taken during panel discussion in CPHI SEA 2025 involving Dr Rebecca, representing Precision Diagnostics
Picture taken during panel discussion in CPHI SEA 2025 involving Dr Rebecca, representing Precision Diagnostics
Pictures taken during the panel session involving Dr Rebecca (in the center), in between of Dr Ngu and Prof Dr Teh, moderated by Mr Ahmad Fazil bin Elias (on the left)

Panel Discussion at the CPHI South East Asia 2025

Precision Diagnostics is proud to share that our CEO, Dr. Rebecca Tay Sook Hui, to participate and partake in a timely and thought-provoking panel discussion at CPHI South East Asia 2025, titled “Pharmacogenomics: Drugs That Kill?’
It was also an honour for Dr. Rebecca to speak alongside;
  • Prof. Dr. Teh Lay Kek, Faculty of Pharmacy, UiTM Puncak Alam
  • Dr. Ngui Lock Hock, Head of Genetics, Hospital Kuala Lumpur

including the moderator, Mr. Ahmad Fazil bin Elias, Assistant Vice President of the Malaysian Bioeconomy Development Corporation. Our sincere thanks to Informa Markets and Bioeconomy Corporation for organizing this important platform to discuss on the revelation of personalized medicine for the future. 

Panel Title at CPHI SEA 2025; Pharmacogenomics - Drugs That Kill?

Reflections from the Session

Picture taken during panel discussion in CPHI SEA 2025 involving Dr Rebecca, representing Precision Diagnostics
Picture taken during panel discussion in CPHI SEA 2025 involving Dr Rebecca, representing Precision Diagnostics

Pharmacogenomics is steadily gaining ground as a valuable tool in optimising drug therapy and reducing adverse drug reactions. However, several key challenges remain:

  • Limited practitioner exposure to genetic testing
  • Gaps in access to actionable patient-level data
  • Integration difficulties with clinical workflows and EMRs

During the session, PRECISE Pharmacogenomics was highlighted as Malaysia’s first clinically recommended genome-wide pharmacogenomics for drug-gene interactions. Developed based on internationally recognised guidelines, PRECISE is designed to support doctors in making more informed prescribing decisions across multiple therapeutic areas.

Picture taken during panel discussion in CPHI SEA 2025 involving Dr Rebecca, representing Precision Diagnostics
Picture taken during panel discussion in CPHI SEA 2025 involving Dr Rebecca, representing Precision Diagnostics

We remain committed to working alongside clinicians, researchers, and healthcare leaders to expand access to personalised diagnostics that are evidence-informed, clinically relevant, and suited for the needs of the Malaysian healthcare landscape.

Recent Events